FIRST QUARTER 2024 (JAN – MAR)
Net sales amounted to
License revenue amounted to
The gross margin was 66 (69) percent.
Operating profit amounted to
Net profit amounted to
Cash flow from operating activities amounted to
This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/
This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.
© Modular Finance, source